Arvinas, Inc.
Status: Publicly traded
Direct answer
Arvinas, Inc. is publicly traded on NASDAQ under the ticker ARVN.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets...
Can you invest in Arvinas, Inc.?
Yes. Arvinas, Inc. trades publicly on NASDAQ as ARVN.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Arvinas, Inc.
Detailed equity research is provided by MarketSnap.